Marc Duey Purchases 30,000 Shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) Stock

Aprea Therapeutics, Inc. (NASDAQ:APRE) Director Marc Duey purchased 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The stock was purchased at an average price of $4.39 per share, for a total transaction of $131,700.00. Following the acquisition, the director now owns 240,113 shares of the company’s stock, valued at $1,054,096.07. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Marc Duey also recently made the following trade(s):

• On Monday, October 14th, Marc Duey purchased 190 shares of Aprea Therapeutics stock. The stock was acquired at an average price of $2.58 per share, with a total value of $490.20.

Aprea Therapeutics Stock Down 1.1 %

APRE stock opened at $4.40 on Friday. Aprea Therapeutics, Inc. has a 52 week low of $2.15 and a 52 week high of $8.85. The business has a 50-day simple moving average of $3.20 and a 200 day simple moving average of $4.17. The company has a market cap of $23.89 million, a PE ratio of -1.33 and a beta of 1.03.

Aprea Therapeutics (NASDAQ:APRE) last issued its earnings results on Monday, August 12th. The company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.05. The company had revenue of $0.56 million during the quarter, compared to analysts’ expectations of $0.10 million. Aprea Therapeutics had a negative net margin of 1,012.37% and a negative return on equity of 56.38%. On average, analysts anticipate that Aprea Therapeutics, Inc. will post -2.74 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Aprea Therapeutics in a research report on Monday, August 12th. Wedbush restated an “outperform” rating and issued a $11.00 price objective on shares of Aprea Therapeutics in a research note on Tuesday, August 13th.

Institutional Investors Weigh In On Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Dimensional Fund Advisors LP acquired a new position in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned about 0.20% of Aprea Therapeutics as of its most recent SEC filing. Institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.